Establishment Labs Holdings Inc. (ESTA)
Establishment Labs: Procedure Economics Strengthens The Bull Case
Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Q2 Earnings Call Highlights
Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.57 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.
Establishment Labs Insider Sells 37,500 Shares as Stock Jumps 128% in a Year
37,500 shares were sold indirectly for a total transaction value of approximately $2.45 million on April 14, 2026. All shares sold were indirectly held via Sariel Group Ltd, with no direct shares sold; after the trade, the insider retains 45,193 direct shares and 1,182,504 indirect shares, per the Form 4.
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.98 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Establishment Labs: The Pivot From Growth To Profitable Scale
Establishment Labs is transitioning to positive cash flow, ending its cash burn era and justifying its premium valuation. ESTA achieved 20% U.S. breast augmentation market share in under 18 months, outpacing historical competitors and establishing a robust commercial platform. Expansion into the reconstruction segment and minimally invasive procedures is set to double ESTA's addressable market and drive at least 25% annual revenue growth through 2027.
Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.
